No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
A Look At The Intrinsic Value Of LanZhou Foci Pharmaceutical Co.,Ltd. (SZSE:002644)
Buddha\'s Pharmaceutical: Report for the third quarter of 2024
Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders
Buddha\'s Pharmaceutical: 2024 Semi-Annual Report Summary
Buddha Tzu Pharmaceuticals: Semi-Annual Report 2024
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 28% Share Price Plunge Could Signal Some Risk
